OAM
EW icon

Oppenheimer Asset Management’s Edwards Lifesciences EW Stock Holding History

Oppenheimer Asset Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.18M Buy
+52,229
New +$4.31M 0.05% 372
2025
Q4 		– Sell
-37,880
Closed -$2.95M – 1144
2025
Q3 		$2.95M Buy
37,880
+13,820
+57% +$1.08M 0.03% 459
2025
Q2 		$1.88M Buy
24,060
+2,361
+11% +$176K 0.02% 577
2025
Q1 		$1.57M Buy
21,699
+4,125
+23% +$295K 0.02% 596
2024
Q4 		$1.3M Buy
17,574
+4,770
+37% +$334K 0.02% 649
2024
Q3 		$845K Sell
12,804
-9,179
-42% -$667K 0.01% 754
2024
Q2 		$2.03M Buy
21,983
+615
+3% +$54.5K 0.03% 519
2024
Q1 		$2.04M Buy
21,368
+6
+0% +$504 0.03% 476
2023
Q4 		$1.63M Sell
21,362
-66,450
-76% -$4.62M 0.02% 570
2023
Q3 		$6.08M Buy
87,812
+4,723
+6% +$380K 0.09% 252
2023
Q2 		$7.84M Sell
83,089
-1,791
-2% -$156K 0.12% 210
2023
Q1 		$7.02M Sell
84,880
-884
-1% -$69.5K 0.11% 215
2022
Q4 		$6.4M Buy
85,764
+2,188
+3% +$169K 0.1% 226
2022
Q3 		$6.91M Buy
83,576
+1,867
+2% +$180K 0.12% 213
2022
Q2 		$7.77M Sell
81,709
-6,473
-7% -$670K 0.13% 189
2022
Q1 		$10.4M Buy
88,182
+1,118
+1% +$125K 0.15% 166
2021
Q4 		$11.3M Buy
87,064
+1,053
+1% +$123K 0.15% 161
2021
Q3 		$9.74M Buy
86,011
+164
+0.2% +$18.7K 0.14% 177
2021
Q2 		$8.89M Buy
85,847
+1,988
+2% +$187K 0.13% 191
2021
Q1 		$7.01M Sell
83,859
-8,962
-10% -$758K 0.11% 217
2020
Q4 		$8.47M Buy
92,821
+3,973
+4% +$330K 0.14% 181
2020
Q3 		$7.09M Buy
88,848
+2,845
+3% +$222K 0.14% 178
2020
Q2 		$5.94M Buy
86,003
+521
+0.6% +$37K 0.12% 199
2020
Q1 		$5.37M Sell
85,482
-12,147
-12% -$876K 0.13% 183
2019
Q4 		$7.59M Sell
97,629
-4,077
-4% -$318K 0.16% 161
2019
Q3 		$7.46M Sell
101,706
-3,531
-3% -$248K 0.17% 154
2019
Q2 		$6.48M Sell
105,237
-5,238
-5% -$317K 0.14% 182
2019
Q1 		$7.05M Sell
110,475
-10,719
-9% -$612K 0.16% 165
2018
Q4 		$6.19M Sell
121,194
-14,085
-10% -$713K 0.15% 158
2018
Q3 		$7.85M Sell
135,279
-29,115
-18% -$1.42M 0.17% 150
2018
Q2 		$7.98M Sell
164,394
-35,799
-18% -$1.67M 0.2% 130
2018
Q1 		$9.31M Buy
200,193
+3,681
+2% +$160K 0.23% 107
2017
Q4 		$7.16M Hold
196,512
– – 0.19% 136
2017
Q3 		$7.16M Sell
196,512
-8,109
-4% -$309K 0.19% 138
2017
Q2 		$8.06M Sell
204,621
-12,429
-6% -$454K 0.22% 120
2017
Q1 		$6.81M Buy
+217,050
New +$6.8M 0.19% 128

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Oppenheimer Asset Management's EW Position: Q1 2026 in Review

Oppenheimer Asset Management opened a new position in Edwards Lifesciences (EW) in Q1 2026: 52,229 shares worth $4.18M. The stake represents 0.05% of the portfolio and ranks #372 among its holdings. This is a return to the name: Oppenheimer Asset Management previously reported a position in EW as recently as Q3 2025.

Oppenheimer Asset Management first reported a position in EW in Q1 2017 and has held it in 36 quarters since. The position peaked at $11.3M in Q4 2021. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Oppenheimer Asset Management held 52,229 shares of Edwards Lifesciences worth $4.18M as of Q1 2026.
  • Edwards Lifesciences was a new Oppenheimer Asset Management position in Q1 2026.
  • Edwards Lifesciences made up 0.05% of Oppenheimer Asset Management's portfolio in Q1 2026, its #372 holding.
  • Oppenheimer Asset Management first reported a position in Edwards Lifesciences in Q1 2017 and has held it in 36 quarters since.
  • Oppenheimer Asset Management's Edwards Lifesciences position peaked at $11.3M in Q4 2021.
  • 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Oppenheimer Asset Management's 13F filing for Q1 2026, filed 24 Apr 2026.